Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 2007年4月,中新创投、王晓航签署《江苏康众数字医疗设备有限公司章程》,约定康众有限注册资本为1,000.0000万元,其中,中新创投出资人民币800.0000万元,王晓航出资200.0000万元,均为货币出资,设立康众有限。2018年2月9日,立信出具信会师报字[2018]第ZA40348号《验资报告》,经审验,截至2018年2月9日,公司已将康众有限截至2017年10月31日经审计的所有者权益188,846,777.50元,按1:0.3500的比例折合股份总额,共计6,609.6770万元,大于股本的部分计入资本公积。2018年6月26日,江苏省工商行政管理局向康众医疗核发《企业法人营业执照》,统一社会信用代码为:913205946617779330。2018年6月27日,康众医疗取得苏州工业园区行政审批局出具的《外商投资企业变更备案回执》(苏园经备201800759)。 公司是一家专业从事数字化X 射线平板探测器研发、生产、销售和服务的企业。公司自设立以来始终致力于深耕数字化X 射线平板探测器行业,坚持自主研发和独立创新,产品应用从医疗普放逐渐延伸至乳腺、动态透视、放疗、口腔三维成像等领域,并进一步拓展至工业、安检、宠物医疗领域,产品形式从固定式发展出移动式、无线便携式等,并逐渐衍生出适配暗盒尺寸、低剂量等特点。经过十余年不懈努力,公司已成长为数字化X 射线平板探测器行业内全球知名、国内领先的企业之一。根据IHS Markit的数据统计,公司2018 年在全球医疗及宠物医疗数字化X 射线平板探测器市场的份额约3.0%,位列全球第九,国内企业第二。公司拥有数字化X 射线平板探测器相关的核心技术和工艺,自主研发的专利和非专利技术覆盖数字化X 射线平板探测器设计、生产、组装、测试等关键阶段,是江苏省高新技术企业。公司目前拥有年产约6,000 台数字化X 射线平板探测器的生产能力,本次发行募集资金投资项目平板探测器生产基地建成达产后,公司将实现产能扩充,进一步巩固并增强行业地位。 公司拥有一支在数字化X 射线平板探测器的集成设计方面具备丰富经验的研发团队,掌握了非晶硅TFT/PD 的设计和制造、碘化铯的蒸镀和封装等关键技术,具备较强的自主研发、设计、创新能力,在数字化X 射线平板探测器的新技术和新应用,如非常规平板探测器的制造和集成技术、金属氧化物MOTFT 技术、人工智能技术、双能成像技术等领域进行了前瞻性的研发布局。公司拥有经验丰富的销售团队,产品销售遍及全国,并远销境外三十多个国家和地区,产品性能与品质获得了客户的广泛认可。公司还亦是行业标准《医用乳腺数字化X 射线摄影用探测器》(YY/T1307—2016)和《医用电气设备 数字X 射线成像装置特性 第1-1 部分:量子探测效率的测定 普通摄影用探测器》(YY/T 0590.1—2018)的起草单位之一,产品具备一定的全球竞争力和较强的进口替代能力。 | ||||||||||||||||||||||||
Main Business | 专业从事数字化X射线平板探测器研发、生产、销售和服务的企业。 | ||||||||||||||||||||||||
Legal Representative | JIANQIANG LIU | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 尹晟 | ||||||||||||||||||||||||
Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
Auditors | 立信会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0512-86860385 | ||||||||||||||||||||||||
Fax No | 0512-86860388 | ||||||||||||||||||||||||
Website | careray.cn | ||||||||||||||||||||||||
ir.careray@careray.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 01/02/2021 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.170 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.054 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 9.736 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 1.407B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |